Circulating Tumor Cell Detection in Lung Cancer: But to What End?

Cancers

Paul Hofman¹  Véronique Hofman¹  Marius Ilié¹  Simon Heeke¹  Charles-Hugo Marquette² 

[1] Laboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, France;Team 4, IRCAN, FHU OncoAge, University Côte d’Azur, CNRS, INSERM, 06107 Nice CEDEX 02, France;

关键词: circulating tumor cells;    liquid biopsy;    lung cancer;    personal medicine;    techniques;    xenograft;   

DOI  :  10.3390/cancers11020262

来源: DOAJ

【 摘 要 】

The understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving understanding within the domain of thoracic oncology. However, the use of these CTCs as prognostic and predictive biomarkers has not been adopted to the same extent as circulating free DNA (cf-DNA) in plasma, in the daily practice of thoracic oncologists. However, recent technological advances have firmly put the detection and characterization of CTCs in thoracic oncology back on the agenda, and have opened up perspectives for their routine clinical use. This review discusses the major advances of using CTCs in the domain of thoracic oncology, as well as the envisaged short- and long-term prospects.

【 授权许可】

Unknown